GLAXO IN AIDS VACCINE PACT

GlaxoSmithKline and the International AIDS Vaccine Initiative agreed to work together in an effort to develop an AIDS vaccine. In a press release, GlaxoSmithKline said the pact will facilitate early research and development of its nonhuman primate adenovirus vaccine vector as a component of an AIDS vaccine. IAVI and the U.K.-based drugmaker will collaborate to advance the development of technology that uses noninfectious vaccine vectors to stimulate specific immune responses directed against HIV, the virus that causes AIDS.

The Street (http://www.thestreet.com/stocks/biotech/10228902.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA)